A Multiple Ascending Dose Study of R1507 in Patients With Advanced Solid Tumors.



Status:Completed
Conditions:Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:8/3/2016
Start Date:April 2006
End Date:April 2011

Use our guide to learn which trials are right for you!

A Dose-escalation Study of R1507 in Patients With Advanced Solid Tumors.

This study will determine the maximum tolerated dose and pharmacokinetic profile of R1507 in
patients with metastatic or locally advanced malignant solid tumors, non-Hodgkin's lymphoma
or Hodgkin's lymphoma. Groups of patients will be sequentially enrolled to receive ascending
doses of R1507 either weekly or three-weekly by intravenous infusion. The starting dose of
1mg/kg iv for each dosing regimen will be escalated in subsequent groups of patients after a
satisfactory assessment of safety, tolerability and pharmacokinetics of the previous dose.
The anticipated time on study treatment is until disease progression or dose-limiting
toxicity, and the target sample size is <100 individuals.


Inclusion Criteria:

- adult patients, >=18 years of age;

- solid neoplasm, non-Hodgkin's lymphoma or Hodgkin's lymphoma;

- metastatic or locally advanced disease, not curable by any currently available
treatment.

Exclusion Criteria:

- severe, uncontrolled systemic disease;

- patients who require treatment with glucocorticoids or immunosuppressive treatment
within last 6 months;

- patients with diabetes mellitus.
We found this trial at
3
sites
New Brunswick, New Jersey 08901
?
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
?
mi
from
Aurora, CO
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials